Some form of pharmacological treatment of migraine is not it With results for all births reported.29 Among the women, who U treatment were compared again, was a separate analysis on the 658, the re-done U sumatriptan. When comparing sumatriptan with pregnancies among pregnancies in the general Bev Lkerung, there were no significant differences in Nutlin-3 birth defects, premature birth, S uglinge Lowbirth weight, perinatal mortality T or multiple births. A small retrospective analysis of data from the database of prescription drugs epidemiological North Jutland compared the results of 34 pregnancies exposed to sumatriptan with 89 pregnancies in migraine Nepatienten that any treatment that may need during the pregnancy were exposed, 15.955 to normal and pregnancies. 30 No F Ll of birth defects or stillbirth have been reported.
The risk of preterm birth was in the sumatriptan group compared with other migraine Ne and normal pregnancies increased Ht, but no data were given regarding the definition of prematurity. Interestingly, increases ht the risk of delivering a baby with low birth weight in all patients with migraine Ne who delivered at term compared to the risk in healthy women, but no conclusions can be drawn from Thus, as data on pregnancies in women with migraine ne are contradictory. Both retrospective analyzes were con well U and using data from databases of government with the task of reducing the risk of recall bias, in the data records Courts, and can be found contr The Observational case studies based on patient reporting.
However, the investigators were able to contr L is the m matched Rfaktoren St, Such as the time of exposure and migraine Ne severity and H FREQUENCY. She finished also reported the results of the tats Chlichen births and do not consider the number of pregnancies following the birth defects identified pr Natal. Summary Pregnant women should always be cautious, taking medications and potential risks must be weighed against the benefits of therapy. Historically, pregnant women with migraine Ne very few options for the treatment had. W While the ideal controlled test The randomized can be conducted in this population for ethical reasons, the existing data on the safe use of sumatriptan are encouraging.
Most of the information from sumatriptan pregnancy registry’s clinical trials and obtained suggest that this drug has no significant influence on organogenesis or spontaneous abortion rate and can be used as a therapeutic alternative s for pregnant women to experience again the onset or worsening of migraine ne-headaches in their first trimester. Readers are cautioned, however, these data on other drugs in this class is not sufficient to draw the same conclusions for all of them. Furthermore, as the majority of data available for sumatriptan exposure during the first quarter alone is involved, or the timing of drug exposure was not reported, caution for use in the neighborhoods weight is ensured And intermediates thereof. prospective studies of sumatriptan, use s sp ter during pregnancy should be promoted found. Emily W Evans PharmD, Assistant Professor, Department of Clinical Sciences and Administration, College of Pharmacy, University of t Offor C / IC, additiona